Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 4/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22328213 | 0.80 | RAB9A (0.38) | IDH1IDH2APPNCF1NPSR1 | |
| SCHEMBL26324947 | 0.79 | GOT1 (0.38) | CYP1A2 | |
| SCHEMBL26441388 | 0.74 | NPSR1 (0.38) | IDH1IDH2APPNCF1NPSR1 | |
| SCHEMBL12883344 | 0.73 | CHRNB2 (0.41) | NCF1CYP1A2 | |
| SCHEMBL18160808 | 0.72 | NCF1 (0.36) | IDH1IDH2APPNCF1NPSR1 | |
| SCHEMBL20436545 | 0.72 | HSD11B1 (0.40) | IDH1IDH2APPNCF1NPSR1 | |
| SCHEMBL22338260 | 0.71 | RAB9A (0.41) | IDH2NPSR1PLK1MEN1RAB9A | |
| SCHEMBL9083546 | 0.70 | SMN1; SMN2 (0.42) | IDH1IDH2CYP1A2MEN1RAB9A | |
| SCHEMBL13626475 | 0.69 | HSD11B1 (0.42) | IDH1IDH2APPNCF1NPSR1 | |
| SCHEMBL22328214 | 0.68 | PLK1 (0.35) | PLK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029731-B2 | Acyl benzo[d]thiazol-2-amine and their methods of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20220396555-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210236470-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 2021-08-05 | — | — | US | disclosed |
| US-20210236471-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-08-05 | — | — | US | disclosed |
| US-20210228549-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-07-29 | — | — | US | disclosed |
| US-10905681-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. | 2020-09-24 | — | — | US | disclosed |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-09-17 | — | — | US | disclosed |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190209532-A1 | ACYL BENZO[D]THIAZOL-2-AMINE AND THEIR METHODS OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2019-07-11 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10905681-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | IDH1 984/4885IDH2 1206/4885APP 2839/4885 |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | IDH1 984/4885IDH2 1206/4885APP 2839/4885 |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | GRIN3A, GRIN1, GRM3 | IDH1 634/4885IDH2 1356/4885APP 1031/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | IDH1 982/4885IDH2 1133/4885APP 2347/4885 |
| US-12029731-B2 | Acyl benzo[d]thiazol-2-amine and their methods of use | BRCA1, ABAT, HDAC1 | IDH1 571/4885IDH2 121/4885APP 1921/4885 |
| US-20210236471-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | IDH1 984/4885IDH2 1206/4885APP 2839/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | IDH1 722/4885IDH2 829/4885APP 2429/4885 |
| US-20190209532-A1 | ACYL BENZO[D]THIAZOL-2-AMINE AND THEIR METHODS OF USE | BRCA1, ABAT, HDAC1 | IDH1 571/4885IDH2 121/4885APP 1921/4885 |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | GRIN3A, GRIN1, GRM3 | IDH1 634/4885IDH2 1356/4885APP 1031/4885 |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | IDH1 982/4885IDH2 1133/4885APP 2347/4885 |
| US-20210236470-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | IDH1 982/4885IDH2 1133/4885APP 2347/4885 |
| US-20210228549-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | IDH1 984/4885IDH2 1206/4885APP 2839/4885 |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | IDH1 984/4885IDH2 1206/4885APP 2839/4885 |
| US-20220396555-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | IDH1 982/4885IDH2 1133/4885APP 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.